IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease,
(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...
Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...
Korea Joongang Daily on MSN1d
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenueCelltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...
The Crohn’s and Colitis Foundation’s 34th annual Torch Gala is set to take place on Saturday, Feb. 8 in Atlanta, with three ...
The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...
According to new research, wearables like an Apple Watch or an Oura smart ring can detect the symptoms and predict flare-ups of chronic bowel inflammatory woes.
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback